Blood‐based markers (BBMs) have recently shown promise to revolutionize the diagnostic
and prognostic work‐up of Alzheimer's disease (AD), as well as to improve the design of …

Results from recent clinical trials of antibodies that target amyloid-β (Aβ) for Alzheimer's
disease have created excitement and have been heralded as corroboration of the amyloid …

With the emergence of Alzheimer's disease (AD) disease-modifying therapies, identifying
patients who could benefit from these treatments becomes critical. In this study, we …

Alzheimer's disease (AD) pathology is thought to progress from normal cognition through
preclinical disease and ultimately to symptomatic AD with cognitive impairment. Recent work …

Anti-amyloid treatments for early symptomatic Alzheimer disease have recently become
clinically available in some countries, which has greatly increased the need for biomarker …

Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in
the clinic but also to facilitate the development and monitoring of effective disease-modifying …

After years of failed attempts to develop a disease-modifying therapy for Alzheimer's
disease, consistent evidence in support of clinical efficacy was finally presented for a …

Abstract Nowadays, Artificial Intelligence (AI) and machine learning (ML) have successfully
provided automated solutions to numerous real-world problems. Healthcare is one of the …

Neurodegenerative disorders such as Alzheimer's disease (AD) represent a mounting public
health challenge. As these diseases are difficult to diagnose clinically, biomarkers of …

Aducanumab has been approved by the US Food and Drug Administration for treatment of
Alzheimer's disease (AD). Clinicians require guidance on the appropriate use of this new …